Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant

International Immunopharmacology

Volumn 3, Issue 1, 2003, Pages 137-146

  Sanderson, Sam D ^a   Cheruku, Srinivasa R ^a   Padmanilayam, Maniyan P ^a   Vennerstrom, Jonathan L ^a   Thiele, Geoffrey M ^b   Palmatier, Matthew I ^c   Bevins, Rick A ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Conformationally biased C5a agonist; Molecular adjuvant; Peptide based nicotine vaccine

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C5A; EPITOPE; FUNCTIONAL GROUP; GLYCOPROTEIN; HAPTEN; IMMUNOLOGICAL ADJUVANT; NICOTINE; PEPTIDE DERIVATIVE; VACCINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; ATTENUATION; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; CONDITIONED REFLEX; CONTROLLED STUDY; DISCRIMINATION LEARNING; DRUG CONJUGATION; DRUG SYNTHESIS; IMMUNIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; TASK PERFORMANCE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; BEHAVIOR, ANIMAL; COMPLEMENT C5A; MOLECULAR SEQUENCE DATA; NICOTINE; PROTEIN CONFORMATION; RATS; VACCINES, SUBUNIT;

EID: 0037238710     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00260-6     Document Type: Article

References (26)

1. US Department of Health and Human Services. The Health Benefits of Smoking Cessation. A Report of the Surgeon General, 1990. Department of Health and Human Services Publication No. (CDC) 90-8416. Rockville, MD: US Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
2. Lucchesi B.R., Schuster C.R., Emley G.S. The role of nicotine as a determinant of cigarette smoking frequency in man with observations of central cardiovascular effects associated with the tobacco alkaloid. Clin. Pharmacol. Ther. 8:1967;789-796.
3. Benowitz N.L., Jacob P., Koslowski L.T., Yu L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N. Engl. J. Med. 315:1986;1310-1313.
4. Hurt R.D. New medications for nicotine-dependent treatment. Nicotine Tob. Res. 1:1999;S175-S179.
5. Hieda Y., Keyler D.E., Vandevoort J.T., Kane J.K., Ross C.A., Raphael D.E.et al. Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther. 283:1997;1076-1081.
6. Keyler D.E., Hieda Y., Peter J.S., Pentel P.R. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob. Res. 3:1999;241-249.
7. Hieda Y., Keyler D.E., VanDeVoort J.T., Niedbala R.S., Raphael D.E., Ross C.A.et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl.). 2:1999;150-157.
8. Pentel P.R., Malin D.H., Ennifar S., Hieda Y., Keyler D.E., Lake J.R.et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65:2000;191-198.
9. Hieda Y., Keyler D.E., Ennifar S., Fattom A., Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 22:2000;809-819.
10. Tuncok Y., Hieda Y., Keyler D.E., Brown S., Ennifar S., Fattom A.et al. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp. Clin. Psychopharmacol. 9:2001;228-234.
11. Tempero R.M., Hollingsworth M.A., Burdick M.D., Finch A.M., Taylor S.M., Vogen S.M.et al. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J. Immunol. 158:1997;1377-1382.
12. Buchner R., Vogen S.M., Sanderson S.D., Ye R.D., Morgan E.L. Anti-human kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide kR(33-52) derived from the predicted amino-terminal region of the human kappa receptor. J. Immunol. 158:1997;1670-1680.
13. Ulrich J.T., Cieplak W., Pacakowski N.J., Taylor S.M., Sanderson S.D. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant. J. Immunol. 164:2000;5492-5498.
14. Vogen S.M., Prakash O., Kirnarsky L., Sanderson S.D., Sherman S.A. Determination of structural elements related to the biological activities of a potent decapeptide agonist of human C5a anaphylatoxin. J. Pept. Res. 54:1999;74-84.
15. Short A.J., Paczkowski N.J., Vogen S.M., Sanderson S.D., Taylor S.M. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. Br. J. Pharmacol. 128:1999;511-514.
16. Sanderson S.D., Kirnarsky L., Sherman S.A., Ember J.A., Finch A.M., Taylor S.M. Decapeptide agonists of human C5a anaphylatoxin: the relationship between conformation and spasmogenic and platelet aggregatory activities. J. Med. Chem. 37:1994;3171-3180.
17. Cushman M., Castagnoli N. The synthesis of trans-3′-methylnicotine. J. Org. Chem. 37:1972;1268-1271.
18. Liehr J.G., Schulze P., Richter W.J. Ring closure reactions in electron impact induced fragmentation of nicotine. Org. Mass Spectrom. 7:1973;45-51.
19. Boyum A. Isolation of lymphocytes, granulocytes, and macrophages. Scand. J. Immunol. Suppl. 5:1976;9-15.
20. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U. S. A. 76:1979;333-337.
21. Pitas R.E., Boyles J., Mahley R.W., Bissell D.M. Uptake of chemically modified low density lipoproteins in vivo is mediated by specific endothelial cells. J. Cell Biol. 100:1985;103-117.
22. Tuma D.J., Klassen L.W. Immune responses to acetylaldehyde-protein adducts: role in alchoholic liver disease. Gastroenterology. 103:1992;1969-1973.
23. Farwell B.J., Ayres J.J.B. Stimulus-reinforcer and response-reinforcer relations in the control of conditioned appetitive headpoking ("goal tracking") in rats. Learn. Motiv. 10:1979;295-312.
24. Bevins R.A., Besheer J., Pickett K.S. Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditional expression. Pharmacol. Biochem. Behav. 68:2001;135-145.
25. Byrnes-Blake K.A., Carroll F.I., Abraham P., Owens S.M. Generation of anti-(+) methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats. Int. Immunopharmacol. 1:2001;329-338.
26. Stolerman I.P., Garacha H.S., Pratt J.A., Kumar R. Role of training dose in discrimination of nicotine and related compounds in rats. Psychopharmacology. 84:1984;413-419.